北美 CRISPR 基因检测和诊断市场 – 2029 年行业趋势和预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

北美 CRISPR 基因检测和诊断市场 – 2029 年行业趋势和预测

  • Medical Devices
  • Published Report
  • May 2022
  • North America
  • 350 页面
  • 桌子數: 103
  • 图号: 48

>北美 CRISPR 基因检测和诊断市场,按类别(第 1 类 - 多种效应蛋白和第 2 类 - 单个 CrRNA 结合蛋白)、产品和服务(产品和服务)、应用(生物医学诊断、基因组工程、药物发现、农业应用和其他)、工作流程(样品制备、预扩增、CrRNA、Cas 酶和传感)、最终用户(医院、诊断中心、生物技术公司、学术和研究机构等)、分销渠道(直接招标、零售销售)划分的行业趋势和预测到 2029 年

北美 CRISPR 基因检测和诊断市场

市场定义和见解

CRISPR 是一种基因组编辑工具,它允许研究人员轻松改变 DNA 序列和修改基因功能。它有许多潜在的应用,包括纠正遗传缺陷以及治疗和预防疾病传播。基于 CRISPR 的诊断方法已用于许多生物医学应用,例如检测传染性和非传染性疾病的核酸生物标志物以及检测遗传疾病。CRISPR 中的检测试剂盒由两部分组成:一种称为 Cas9 的蛋白质和一种向导 RNA,即一串具有特定遗传密码的核酸分子。

CRISPR 基因检测和诊断市场

CRISPR 基因检测和诊断市场

该 CRISPR-Cas9 系统已针对哺乳动物细胞进行了修改。我们可以通过非同源末端连接 (NHEJ) 引入移码突变,从而引入特定于我们感兴趣的基因的引导序列 (sgRNA) 来敲除特定基因,或者产生敲入突变。

CRISPR-Cas 9 系统扩大了基因和细胞治疗的诊断和服务范围。制药公司在研发方面投入巨资以开发新产品,大量基因和细胞治疗药物进入早期开发阶段。市场参与者的投资将为急需治疗的患者提供安全有效的治疗方案。

北美 CRISPR 基因检测和诊断具有支持作用,旨在减轻症状的严重程度。Data Bridge Market Research 分析,在 2022 年至 2029 年的预测期内,CRISPR 基因检测和诊断市场将以 19.6% 的复合年增长率增长。

报告指标

细节

预测期

2022 至 2029 年

基准年

2021

历史岁月

2020(可定制至 2019 - 2014)

定量单位

收入(百万美元),定价(美元)

涵盖的领域

按类别(第 1 类 - 多种效应蛋白和第 2 类 - 单个 CrRNA 结合蛋白)、产品和服务(产品和服务)、应用(生物医学诊断、基因组工程、药物发现、农业应用等)、工作流程(样品制备、预扩增、CrRNA、Cas 酶和传感)、最终用户(医院、诊断中心、生物技术公司、学术和研究机构等)分销渠道(直接招标、零售)

Countries Covered

U.S., Canada and Mexico

Market Players Covered

GenScript, OriGene Technologies, Inc., Applied StemCell, GeneCopoeia, Inc., Agilent Technologies, Inc., Synthego, BioVision Inc., Hera Biolabs, Cellecta, Inc., New England Biolabs, 10x Genomics, addgene CasTag Biosciences, Merck KGaA, Integrated DNA Technologies, Inc. (A subsidiary of Danaher), Thermo Fisher Scientific Inc. among others

 North America CRISPR Gene Detection and Diagnostic Market Dynamics

Drivers

  • Rise in prevalence and incidence of chronic diseases

Chronic diseases are common health conditions, where one in three the adults suffer from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens.

CRISPR is abbreviated as clustered regularly interspaced short palindromic repeats. In recent years, CRISPR has become a commanding tool for gene editing, which is used to alter the specific sequences of DNA in a cell. CRISPR has important use in the research and treatment of Huntington’s disease, muscular dystrophy, cancer and high cholesterol.

For instance,

  • In 2021, the data by NORD - National Organization for Rare Disorders, Inc. stated the diagnosed incidence of Duchenne Muscular Dystrophy (DMD). The Duchenne Muscular Dystrophy (DMD) is a frequent genetic condition, which affects 1 in 3,500 male births worldwide
  • Rise In Investment In Research And Development

Gene editing technologies, such as the CRISPR-Cas 9 system, have extended the scope of diagnostics and services in gene and cell therapies. Pharmaceutical companies invest heavily in R&D to develop new products, with a surge of gene and cell therapy agents entering early development. The market players investing would allow to achieve the goal of producing safe and effective treatments for patients in serious need.

For instance,

  • In February 2022, Synthego had raised USD 200 million as an investment for research and development to boost the development of CRISPR-Based Medicines from early-phase research to the clinic. Synthego will use the investment amount from Series E finance to accelerate the creation of CRISPR diagnostics and services

Availability of funding for CRISPR gene diagnostics

CRISPR gene diagnostics and research are funded by the National Institute of Health (NIH) budget. The private sector also funds the CRISPR gene detection and research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With genome editing being such a new field, an unbiased governmental body must supervise them; the FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries., will further enhance the growth of the CRISPR gene detection and diagnostic market.

Furthermore, advancement in CRISPR gene diagnostics, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the CRISPR gene detection market. Other factors such as increase in the demand for effective therapies and rising awareness about the timely diagnosis and will positively impact the CRISPR gene detection and diagnostic market's growth rate. Additionally, high disposable income, rising number of chronic diseases, changing lifestyle will result in the expansion of the CRISPR gene detection and diagnostic market.

Opportunities

  • The rise in healthcare expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.

  • Strategic initiative by market players

The demand for CRISPR gene detection and diagnosis has increased the demand in the U.S. and owing to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

  • In May 2021, Horizon Discovery Ltd. extended the gene modulation portfolio with the first synthetic single guide RNA and patent pending dcas9 repressor for CRISPR interference in Waltham. The expansion of the portfolio had increased the sales and revenue of the synthetic guide RNA portfolio across the U.S. and the U.K. region and had increased the collaboration with market players

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the CRISPR gene detection and diagnostic market in the forecast period of 2022-2029. Also, high unmet need of current and developments in healthcare technology will escalate the growth rate of the CRISPR gene detection and diagnostic market in future.

Restraints/Challenges

However, high cost of CRISPR diagnostics and risks faced while using the CRISPR diagnostics will impede the growth rate of CRISPR gene detection and diagnostic market. Additionally, the risks incurred while using the MRI devices will hinder the CRISPR gene detection and diagnostic market growth. The lack of skilled expertise and regulations will further challenge the market in the forecast period mentioned above.

  • Rise in cost of CRISPR based diagnostics

The vast potential of CRISPR based therapeutics comes with a cost tag. Maximum genome editing therapies require an increased amount of time for development and production, and hence the rise in cost occurs. Besides, the assay kits and medications related to CRISPR gene detection and diagnostic are applicable to large section of population. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend in the future.

For instance,

  • In July 2021, according to Integrated DNA Technologies, Inc., the first commercially available CRISPR-based diagnostic assay for SARS-CoV-2 including reverse transcription LAMP (RT-LAMP) as pre-amplification is currently available at USD 30.15 per reaction

The CRISPR gene detection and diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on CRISPR gene detection and diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

According to a study by Globocan. In 2020, breast cancer had high incidence of cases, around 11.7%, followed by lung cancer which is 11.40%, colorectum cancer which is 10.00%, and cervix uteri and oesophagus cancer having less number of incident cases.

CRISPR gene detection and diagnostic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on the CRISPR Gene Detection and Diagnostic Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

  • In August 2020, SHERLOCK BIOSCIENCES announced a collaboration with Dartmouth-Hitchcock Health, to conduct the clinical trial of SHERLOCK Diagnostic Kit for Sars-CoV-2. The kit received emergency approval from the Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).

North America CRISPR Gene Detection and Diagnostic Market Scope

The CRISPR gene detection and diagnostic market is segmented on the basis of six segments: class, products & services, application, workflow, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Class

  • Class 1- Multiple Effector Proteins
  • Class 2 -Single CrRNA Binding Protein

On the basis of class, the CRISPR gene detection and diagnostic market is segmented into class 1- multiple effector proteins and class 2 -single CrRNA binding protein.

Products & Services

  • Products
  • Services

On the basis of products & services, the CRISPR gene detection and diagnostic market is segmented into products & services.

Application

  • Biomedical Diagnostics
  • Genome Engineering
  • Drug Discovery
  • Agricultural Applications
  • Others

On the basis of application, the CRISPR gene detection and diagnostic market is segmented into is segmented into biomedical diagnostics, genome engineering, drug discovery, agricultural applications and others.

Workflow

  • Sample Preparation
  • Pre-Amplification
  • CrRNA
  • Cas Enzymes
  • Sensing

On the basis of workflow, the CRISPR gene detection and diagnostic market is segmented into sample preparation, pre-amplification, CrRNA, Cas enzymes and sensing.

End User

  • Hospitals
  • Diagnostic Centers
  • Biotechnology Companies
  • Academic and Research Institutes
  • Others

On the basis of end user, the CRISPR gene detection and diagnostic market is segmented into hospitals, diagnostic centers, biotechnology companies, academic and research institutes and others.

Distribution Channel

  • Direct Tenders
  • Retail Sales

CRISPR 基因检测和诊断市场

On the basis of distribution channel, the CRISPR gene detection and diagnostic market is segmented into direct tenders and retail sales.

CRISPR Gene Detection and Diagnostic Market Regional Analysis/Insights

The North America CRISPR gene detection and diagnostic market is analysed and market size insights and trends are provided by regions, class, products & services, application, workflow, end user, and distribution channel as referenced above.

The countries covered in the CRISPR gene detection and diagnostic market report are U.S., Canada and Mexico.

The U.S. dominates the CRISPR gene detection and diagnostic market due to the rise in healthcare expenditure.

报告的国家部分还提供了影响单个市场因素和国内市场法规变化,这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

竞争格局和CRISPR 基因检测与诊断市场份额分析

北美 CRISPR 基因检测和诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对 CRISPR 基因检测和诊断市场的关注有关。

CRISPR 基因检测和诊断市场的一些主要参与者包括 GenScript、OriGene Technologies, Inc.、Applied StemCell、GeneCopoeia, Inc.、Agilent Technologies, Inc.、Synthego、BioVision Inc.、Hera Biolabs、Cellecta, Inc.、New England Biolabs、10x Genomics、addgene CasTag Biosciences、Merck KGaA、Integrated DNA Technologies, Inc.(丹纳赫的子公司)、Thermo Fisher Scientific Inc. 等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 CLASS SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE)

6 EPIDEMIOLOGY

7 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO

8 PIPELINE ANALYSIS FOR NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES

9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT

9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS

9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC

9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS

9.2 RESTRAINTS

9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS

9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS

9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH

9.2.4 AVAILABILITY OF ALTERNATIVES

9.3 OPPORTUNITIES

9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS

9.3.2 RISE IN HEALTHCARE EXPENDITURE

9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS

9.4 CHALLENGES

9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS

9.4.2 STRINGENT REGULATIONS

10 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS

10.1 OVERVIEW

10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN

10.2.1 BIOMEDICAL DIAGNOSTICS

10.2.2 AGRICULTURAL APPLICATIONS

10.2.3 GENOME ENGINEERING

10.2.4 DRUG DISCOVERY

10.2.5 OTHERS

10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS

11 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES

11.1 OVERVIEW

11.2 PRODUCTS

11.2.1 ASSAY KITS

11.2.1.1 SGRNA KIT

11.2.1.2 GENOMIC DETECTION KIT

11.2.1.3 OTHERS

11.2.2 PROTEINS

11.2.2.1 CAS9

11.2.2.2 CPF1

11.2.2.3 OTHERS

11.2.3 PLASMID AND VECTOR

11.2.4 LIBRARY

11.2.5 CONTROL KITS

11.2.6 DELIVERY SYSTEM PRODUCTS

11.2.7 DESIGN TOOLS

11.2.8 GENOMIC RNA

11.2.9 HDR BLOCKERS

11.2.9.1 AZIDOTHYMIDINE

11.2.9.2 TRIFLUOROTHYMIDINE

11.2.9.3 OTHERS

11.2.9.4 OTHERS

11.3 SERVICES

11.3.1 G-RNA DESIGN

11.3.2 CELL LINE ENGINEERING

11.3.3 MICROBIAL GENE EDITING

11.3.4 DNA SYNTHESIS

11.3.5 OTHERS

12 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 BIOMEDICAL DIAGNOSTICS

12.2.1 CANCER

12.2.2 BLOOD DISORDERS

12.2.3 HEREDITARY DISORDERS

12.2.4 MUSCULAR DYSTROPHY

12.2.5 AIDS

12.2.6 NEURODEGENERATIVE CONDITION

12.2.7 OTHERS

12.3 AGRICULTURAL APPLICATIONS

12.4 GENOME ENGINEERING

12.4.1 CELL LINE ENGINEERING

12.4.2 HUMAN STEM CELLS

12.5 DRUG DISCOVERY

12.6 OTHERS

13 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW

13.1 OVERVIEW

13.2 CRRNA

13.3 CAS ENZYME

13.4 PRE-AMPLIFICATION

13.4.1 PCR

13.4.2 LAMP

13.4.3 RPA

13.5 SAMPLE PREPARATION

13.6 SENSING

13.6.1 FLUORESCENT PROBES

13.6.2 COLORIMETRIC

14 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER

14.1 OVERVIEW

14.2 BIOTECHNOLOGY COMPANIES

14.3 ACADEMIC AND RESEARCH INSTITUTES

14.4 DIAGNOSTIC CENTERS

14.5 HOSPITALS

14.6 OTHERS

15 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL SALES

16 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 CANADA

16.1.3 MEXICO

17 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 THERMO FISHER SCIENTIFIC INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 MERCK KGA

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 AGILENT TECHNILOGIES, INC

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER)

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 GENSCRIPT

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 10 X GENOMICS

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENTS

19.7 APPLIED STEM CELL

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 ADDGENE

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BIOVISION INC.

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CELLECTA, INC

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENTS

19.11 CAS TAG BIOSCIENCES

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 GENECOPOEIA, INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 PRODUCT PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 HORIZON DISCOVERY LTD

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 HERA BIOLABS

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 NEW ENGLAND BIOLABS

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENTS

19.16 ORIGENE TECHNOLOGIES, INC.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 SYNTHEGO

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 TAKARA BIO INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

19.19 TOOLGEN, INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

表格列表

TABLE 1 PIPELINE ANALYSIS FOR NORTH AMERICA CRISPR GENE THERAPEUTICS

TABLE 2 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA CLASS-1 MULTIPLE EFFECTOR PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA AGRICULTURAL APPLICATIONS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA DRUG DISCOVERYIN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA CRRNA IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA CAS ENZYME IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA SAMPLE PREPARATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA DIAGNOSTIC CENTERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA HOSPITALS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA DIRECT TENDER IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA RETAIL SALES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 53 NORTH AMERICA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 54 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 56 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 57 U.S. CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 59 U.S. PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 U.S. ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 61 U.S. HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 62 U.S. PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 63 U.S. SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 65 U.S. GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 66 U.S. BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 67 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 68 U.S. PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 69 U.S. SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 70 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 71 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 73 CANADA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 75 CANADA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 CANADA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 77 CANADA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 78 CANADA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 79 CANADA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 81 CANADA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 82 CANADA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 83 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 84 CANADA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 85 CANADA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 86 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 87 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 88 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 89 MEXICO CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 90 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)

TABLE 91 MEXICO PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 MEXICO ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 93 MEXICO HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 94 MEXICO PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 95 MEXICO SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 97 MEXICO GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 98 MEXICO BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 99 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 100 MEXICO PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 101 MEXICO SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)

TABLE 102 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 103 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DBMR POSITION GRID

FIGURE 8 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN TECHNOLOGICAL ADVANCEMENTS IN CRISPR DIAGNOSTICS, AND GOVERNMENT FUNDING FOR THE DEVELOPMENT OF CRISPR DETECTION KITS ARE EXPECTED TO DRIVE THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 TO 2029

FIGURE 13 CLASS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 & 2029

FIGURE 14 NORTH AMERICA CRISPR GENE PATENT SCENARIO, BY APPLICATION

FIGURE 15 CRISPR PATENT LANDSCAPE AND NUMBER OF APPLICATIONS OF NEW PATENT FAMILIES FILED WORLDWIDE, 2001 TO 2019

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET

FIGURE 17 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020

FIGURE 18 PREVALENCE OF HUNTINGTON’S DISEASE IN 2019

FIGURE 19 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2021

FIGURE 20 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2022-2029 (USD MILLION)

FIGURE 21 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, CAGR (2022-2029)

FIGURE 22 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, LIFELINE CURVE

FIGURE 23 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2021

FIGURE 24 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2022-2029 (USD MILLION)

FIGURE 25 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2022-2029)

FIGURE 26 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE

FIGURE 27 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2021

FIGURE 28 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 29 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 30 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 31 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2021

FIGURE 32 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2022-2029 (USD MILLION)

FIGURE 33 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, CAGR (2022-2029)

FIGURE 34 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, LIFELINE CURVE

FIGURE 35 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2021

FIGURE 36 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 37 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)

FIGURE 38 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 40 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 41 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 42 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SNAPSHOT (2021)

FIGURE 44 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021)

FIGURE 45 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)

FIGURE 47 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS (2022-2029)

FIGURE 48 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

On the basis of application, the North America CRISPR Gene Detection and Diagnostic Market is segmented into Biomedical Diagnostics, Genome Engineering, Drug Discovery, Agricultural Applications, and Others.
The North America CRISPR Gene Detection and Diagnostic Market is to grow at a CAGR of 8.40% during the forecast by 2029.
The major players operating in the North America CRISPR Gene Detection and Diagnostic Market are GenScript, OriGene Technologies, Inc., Applied StemCell, GeneCopoeia, Inc., Agilent Technologies, Inc., Synthego, BioVision Inc., Hera Biolabs, Cellecta, Inc., New England Biolabs, 10x Genomics, addgene CasTag Biosciences, Merck KGaA, Integrated DNA Technologies, Inc. (A subsidiary of Danaher), Thermo Fisher Scientific Inc. among others.
The major countries covered in the North America CRISPR Gene Detection and Diagnostic Market are U.S., Canada and Mexico.